Prolacta Bioscience Applauds Recent Legislative Changes
Prolacta Bioscience, the world leader in providing human milk-based nutritional products for critically ill and premature infants, has publicly commended the state legislature for passing significant laws that will improve the nutritional care for vulnerable infants. This recent development signifies a pivotal shift in the way insurance coverage is managed for human milk and related products.
Understanding the New Legislation
The newly enacted laws expand health insurance coverage to include pasteurized donor human milk as well as derivative products, such as human milk fortifiers, for use in outpatient settings. This legislation is seen as a monumental step towards health equity, allowing for greater access to essential nutrition for infants after they leave the hospital environment.
The Importance of Human Milk
While a mother's own milk remains the gold standard for infant nutrition, many situations arise where it is not available. In these cases, donor human milk serves as a vital alternative. The availability of this milk is particularly paramount for premature and critically ill infants who require additional support in their early days. This legislation recognizes and addresses the necessity of ensuring these infants continue to receive the nutrition they require.
Voices from Leadership
Scott Elster, CEO of Prolacta Bioscience, expressed gratitude towards the leadership involved in the passage of this bill, particularly appreciating the efforts from the state's governor and legislature. Elster emphasized that this development represents a tremendous benefit for families, highlighting how critical it is to ensure that nutritional support is accessible even after hospital discharge.
Broader Implications of the Legislation
This legislative amendment signifies more than just an adjustment in insurance policies. It embodies a commitment to improving health outcomes for the most vulnerable infants. Additionally, it implies a shift in mindset among lawmakers regarding the importance of supporting families with preterm infants during challenging times. Advocates hope this trend will inspire similar actions in other regions, pushing for wider availability of donor human milk and its products across the country.
Community Support and Advocacy
Assemblywoman Michaelle Solages, a significant proponent of the legislation, echoed the sentiments shared by Prolacta’s leadership. She reiterated the challenges parents face when attempting to secure coverage for necessary donor milk products after leaving the hospital. Solages praised the countless advocates who advocated for this crucial legislation, expressing a heartfelt thank you to all those who helped voice the needs of families around the state.
About Prolacta Bioscience
Prolacta Bioscience is dedicated to advancing the science of human milk, aiming to enhance health outcomes for critically ill and premature infants. With over 100,000 infants benefitting from their innovative milk-based products, Prolacta operates the first pharmaceutical-grade processing facilities focusing on human milk, adhering to rigorous safety and quality standards. Their unique vat pasteurization process effectively ensures the nutritional integrity and bioactivity of the milk while nullifying harmful pathogens.
Prolacta's Commitment to Quality
The company is renowned not just for its innovative products but also for maintaining the highest standards in milk processing. Their commitment to excellence has made them a trusted name in neonatal nutrition, with the aim of continuously supporting vulnerable infants and their families.
Frequently Asked Questions
What does the new legislation entail?
The new legislation provides health insurance coverage for pasteurized donor human milk and related products for outpatient use, enhancing access for vulnerable infants.
Why is donor human milk important?
Donor human milk is crucial for infants who cannot receive their mother's own milk, particularly for premature and critically ill babies requiring specialized nutrition.
How does this affect families with preterm infants?
This legislation alleviates concerns for families by ensuring continued access to necessary nutritional products post-hospitalization.
What role did Prolacta Bioscience play in this achievement?
Prolacta Bioscience actively supported the proposed legislation, providing insight into the needs of families, and advocating for improved health outcomes for infants.
How can families get involved or learn more?
Families are encouraged to stay informed through advocacy groups and can reach out directly to Prolacta for resources and support regarding the use of donor human milk.
